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A b s t r a c t
A seminal article of Takahashi et al. reporting concomitant accumulation of cellular prion protein (PrPc) and β-amy-
loid (Aβ) in dystrophic neurites, within neuritic plaques raised an exciting issue that is important for our under-
standing of mechanisms of neurodegeneration. The mentioned authors interpreted their findings rather cautiously, 
however since the time of their publication, several reports representing different approaches and methods have 
seemed to indicate that both proteins appear to co-operate more intrinsically than it could have been imagined 
earlier. The goal of the review is to sum up the accruing research data with special attention to evidence pointing to 
the co-operative role of PrPc and Aβ in cognitive impairment.
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Introduction
Though Alzheimer’s disease (AD) and Creutz feldt-
Jakob disease (CJD) are characterized by distinct 
neuropathological changes, they share common pa- 
thological features. They are both conformational 
diseases, related to accumulation of altered proteins, 
which results in a loss of global cognitive functions. 
Alzheimer’s disease is a predominant neurodegener-
ative disorder characterized by two major pathologi-
cal changes: amyloid plaques and neurofibrillary tan-
gles. Amyloid plaques are extracellular formations 
consisting of β-amyloid (Aβ) and cellular material 
outside and around neurons. Neurofibrillary tangles 
are intracellular aggregates of microtubule-associ-
ated tau protein, which has become hyperphospho-
rylated and misfolded. Creutzfeldt-Jakob disease is 
a rapidly progressive brain disease caused by infec-
tious-like self-perpetuating mechanism leading to 
conversion of physiological cellular prion protein 
(PrPc) to its Scrapie conformation (PrPSc) [52]. PrPSc 
creates extremely stable forms, which accumulate in 
infected tissue resulting in its spongiform degene-
ration [53]. There are little data concerning interac-
tions between prion proteins and Aβ, both in their 
physiological and conformationally changed form 
with regard to cognitive functions and dementia. 
Takahashi et al. reported concomitant accumulation 
of PrPc with Aβ in dystrophic neurites within one of 
the amyloid plaque types, called neuritic plaques 
[82]. Also Aβ was found to be deposited with PrPSc in 
CJD [26]. Due to the suspicious findings of those pro-
teins within the same individual, speculations arise 
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around the possibility of connection between the 
pathophysiological processes occurring in these two 
neuropathological conditions [9,70]. These interac-
tions may also have an impact on cognitive perfor-
mance. Therefore, the following question arises: do 
prions and Aβ co-operate in cognitive impairment? 
Here, we review recent findings at the crossroads of 
cognitive neuroscience and neuropathology in order 
to expose the independent role of these proteins 
in cognition and their possible interactions, and to 
seek the answer to this question.
Prion protein
PrPc is a highly conserved protein, which may be 
found in most of vertebrates, at every stage of their 
development and in all types of tissues, especially 
in the nervous system [79]. PrPc is a glucolipid-an-
chored cell membrane sialoglycoprotein, which is lo- 
calized in raft-like microdomains [57]. It is presented 
on the presynaptic and postsynaptic membranes 
[91] of neurons, of many brain areas including hip-
pocampus and the cortex [73]. Membrane-anchored 
PrPc passes internalization and recycling through 
the endosomal pathway [58]. It becomes internal-
ized and degraded in lysosomes [68] or is released 
into the extracellular space [77]. Proposed roles in 
the physiology of this protein are related to its local-
ization on the cell surface. PrPc may act as a cellular 
adhesion molecule which plays a part in neurite out-
growth, neuronal differentiation and survival [54]. 
These functions are consistent with a finding that 
PrPc can associate with surface proteins like lami-
nin, laminin receptor precursor, and the neural cell 
adhesion molecule (NCAM) [6]. Animal studies have 
also revealed that absence of PrPc is connected with 
disrupted olfactory physiology and behaviour [79], 
altered circadian clock, modification of sleep pattern 
[37], and increased sensitivity to seizures [85]. New 
reports bring new data indicating various potential 
features of this protein, making it difficult to find its 
one consistent function.
A growing number of works on mice models and 
on humans indicate a possible role of prion protein 
in the area of cognitive functions. The most common 
source of those reports comes from mice mo dels 
of PrPc gene ablation or over-expression. PrPc null 
mice presented hippocampus-dependent spatial 
learning and memory consolidation impairment 
[23]. Interestingly, those changes were reversed by 
re-expression of PrPc [12]. Additionally, deficiency 
of this protein may cause attention deficits [56]. 
Knockout mice were also more vulnerable to age-re-
lated decline in memory [20] and motor processes 
[64]. Moreover, PrPc over-expression leads to hyper-
activity, increased preference for visual, tactile and 
olfactory stimuli associated novelty [73]. Also it is 
noteworthy that a five-fold increase in PrPc expres-
sion in comparison to wild type mice results in an 
increased resistance against age-related cognitive 
decline [72]. Due to the plenty of PrPc functions there 
are many possible molecular mechanisms in which 
this protein affects cognitive processes. PrPc is local-
ized in the synaptic area, and it may interact with 
other proteins in this structure, playing a role in the 
synaptic plasticity [91]. An in vitro study has revealed 
that recombinant PrP (rPrP) induces rapid processing 
of both axons and dendrites as well as it increases 
the number of new synapses [40]. Consistently, dele-
tion of PrPc resulted in impaired LTP together with 
a decrease in fast GABA-A receptor-dependent inhi-
bition [21,22]. Perhaps changes in LTP are associated 
with the ability of PrPc to make physical interaction 
with receptors for the glutamate. It has been shown 
that PrPc is able to co-immunoprecipitate with NR2D 
subunit of the NMDA, suggesting its possible direct 
modulation [6]. Transgenic (Tg) mice lacking PrPc 
showed enhanced NMDA-induced currents, which 
became reversed after its over-expression [42]. PrPc 
also affects kainate receptors [71] and metabotropic 
glutamate receptors [4] suppressing neuronal excit-
ability through many different mechanisms. Note-
worthy, it has been proved that the range of synap-
tic responses increased with the (higher) level of the 
PrPc expression within glutamatergic synaptic trans-
mission in the hippocampus, but the overall prob-
ability of transmitter release appeared unchanged 
[12]. This example shows that PrPc-dependent mod-
ulation of glutamatergic stimulation and plasticity is 
more complex than just the control of the level of 
neurotransmitter. Regulation of glutamate signaliza-
tion within synapses is important not only because 
of plasticity, but also due to the fact that abnormal 
Ca2+ currents, caused by aberrant activation of the 
NMDA receptor, results in excitotoxicity [32], which 
leads to neurodegeneration. Experiments men-
tioned above indicate that PrPc modulates this pro-
cess. This neuroprotective mechanism may be the 
second way in which PrPc is involved in cognitive 
functions. Tg mice expressing modified PrP (with-
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out its central region residues 105-125 – ΔCR PrP), 
resulted in massive excitotoxic degeneration of cere-
bellar granule neurons [15,51]. There is evidence that 
PrPc also plays a role in neuroprotection through 
the regulation of intracellular signalling cascades, 
mediating cellular survival [55], and its over-expres-
sion protects cell lines from apoptosis. Protective 
activity has been also proved in glia cells. PrPc act-
ed as a radical scavenger in both ROS-rich solution 
and astrocytes cultures in vitro, and its activity was 
essential in their protection against oxidative stress. 
This feature may reflect its protective functions in 
conditions similar to those observed during neuro-
degeneration and ischemia [5]. Another defensive 
mechanism is associated with the ability of PrPc to 
bind co-chaperon molecule, called stress-inducible 
protein 1 (STI1). They create a complex that acts as 
a survival and differentiation promoter [88]. Intrigu-
ingly, blocking the connection between PrPc, STI1 
and laminin adversely influences memory [18,19]. 
There are only scarce data indicating cognitive func-
tions of PrPc in humans, but they bring promising 
results. One epidemiological study of 1322 elderly 
participants revealed that subjects in higher serum 
PrPc quintiles appeared to have lower cognitive func-
tioning scores than those in the lowest PrPc quintile. 
There are two proposed mechanisms of serum PrPc 
elevation. Either there is reduced nerve cell integrity, 
or a higher serum PrPc level reflects the abundance 
of PrPc in neuro-cellular membranes [8].
Exploratory analysis of 335 healthy volunteers 
revealed that even SNP of the PrPc gene might 
influence cognitive functions in humans, especial-
ly a common polymorphism at codon 129, which 
results in the translation of methionine or valine on 
a short β-sheet region in the C-terminal domain of 
the protein [77]. Methionine at codon 129 is asso-
ciated with lower scores on several subscales of 
HAWIE-R subscales (German version of the Wechsler 
Adult Intelligence Scale Revised), especially with the 
Digit Symbol subtest. Interestingly, PrP-IQ associa-
tion was the strongest in the less educated individ-
uals; as opposed to other studies showing that the 
genetic influence on IQ is higher among higher edu-
cated families [76]. The same polymorphism is asso-
ciated with the reduction of white matter in a group 
of healthy volunteers and patients with schizophre-
nia [78]. However studies on long-term memory 
revealed that healthy subjects presenting the same 
Met129 yielded the highest effect size, recalling 
17 percent more words twenty four hours after the 
list-learning task than carriers of Val129 gene type, 
but there was no significant difference between 
those groups in short-term memory. Authors of this 
study hypothesize that despite the fact that Met129 
allele may facilitate self-perpetuating conformatio-
nal changes of the human prion protein, it may have 
a beneficial effect on long-term memory by hypo-
thetical prion-based mechanism [66]. Studies men-
tioned above revealed that PrPc and its gene may 
aspire to the role of a potential biomarker of cogni-
tive measurements. The scarcity of investigations in 
humans and a plenty of possible mechanisms limit 
possibilities to draw a definite conclusion as for the 
existence of one causative relation between PrPc 
and cognition. In spite of divergence of its functions, 
subserving somewhat unrelated processes, there 
is a prospect to indirectly indicate common ground 
of its activity. PrPc may act as a protein, involved in 
global protection of the organism in a micro- and 
macroscopic perspective: at the microscopic (cellu-
lar) level – protecting the cell against apoptotic fac-
tors, ROS, excitotoxicity, toxins and at a macrosco-
pic level – affecting the whole organism, by playing 
a significant role in cognition, especially in defensive 
attention, spatial and long-term memory and also 
olfactory physiology and behaviour (crucial for the 
survival chances of an animal).
β-amyloid
β-amyloid is a peptide consisting of 36-43 ami-
no acids which originates from the cleavage of the 
transmembrane glycoprotein called amyloid pre-
cursor protein (APP), by the proteolytic activation 
of α-, β- and γ-secretase [80]. Generation of Aβ 
may occur in the neuronal axonal membranes and 
is preceded by APP-mediated axonal transport of 
β-secretase and presenilin-1 [39]. Amyloid precursor 
protein is cleaved by β-secretase, producing soluble 
and a cell-membrane bound fragment of APP [46], 
which is then cleaved by γ-secretase. This reaction 
produces APP intracellular domain (AICD) associ-
ated with the regulation of gene transcription and 
Aβ, which is released to plasma, cerebrospinal fluid 
and brain interstitial fluid [30,90]. It has been estab-
lished that Aβ39-42 are hydrophobic self-aggregating 
peptides, of which Aβ42 is a major component of 
senile plaques observed in AD, but it still remains 
controversial how those peptides are involved in the 
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cognitive decline observed during this disease [36]. 
The “Aβ cascade hypothesis” suggests the major role 
of amyloid plaques, especially fibrillar Aβ ones in the 
aetiology of AD, reporting a correlation between the 
amount of those formations and cognitive dysfunc-
tions [3,24,25,35,67]. Recent studies with the use 
of detailed measures of Aβ pathology suggest an 
opposite explanation. Research on APPswe/PS1ΔE9 
double transgenic mice (well-established model of 
AD) has revealed that hippocampal soluble Aβ1-40 
and Aβ1-42 levels were highly correlated with spatial 
learning and long-term contextual memory impair-
ments. Also, hippocampal soluble Aβ1-40 and Aβ1-42 
levels were strongly correlated with spatial memo-
ry impairments, but no correlations were observed 
between mentioned cognitive functions and amy-
loid plaque formations such as: total Aβ plaque load, 
fibrillar Aβ plaque load and also insoluble Aβ levels. 
Authors of this study revealed that a tiny fraction 
of soluble peptides in the hippocampus and cor-
tex is an independent factor in predicting cognitive 
impairments in this transgenic mice model, suggest-
ing “soluble Aβ hypothesis” as a major mechanism 
of cognitive decline in AD [89]. Consistently with this 
hypothesis, experiments on young domestic chicks 
show that an injection of soluble Aβ 5 minutes prior 
to training caused memory loss, due to the consoli-
dation failure 35 minutes later [31]. Also, reduction of 
soluble Aβ42 or Aβ42 and Aβ40 by γ-secretase modula-
tors (GSMs) ameliorated cognitive deficits in Tg2576 
plaque-free mice model of AD. However, a later study 
suggests that newly synthesized soluble Aβ42 may 
play a more significant role in cognitive impairments 
than plaque-associated soluble Aβ [61]. Injections of 
Aβ to rats result in rapid cognitive disruption, show-
ing a direct interference with the cognitive func-
tions not only through neurodegeneration, but also 
through interruption of their cellular mechanisms 
[17,50,69]. It has been shown that Aβ impairs hippo-
campal long-term potentiation (LTP) by deterioration 
of tetanus-induced activation of guanylate cyclase 
and increase of cGMP. Those changes prevent protein 
kinase G activation and phosphorylation of GluR1, 
finally resulting in impaired translocation of AMPA 
receptors to synaptic membranes [62]. Interactions 
of Aβ with nicotinic, insulin and glutamatergic recep-
tors may also have an impact on synaptic plasticity 
and spine formation [17,50,63]. These mechanisms 
explain why injection of Aβ oligomers before the 
acquisition of new information disrupts the process 
of the consolidation without affecting its retrieval, 
when the information was properly stored [28]. Fur-
thermore, it has been shown that Aβ may have an 
impact on the cognitive function through its influ-
ence on NADPH oxidase enzyme (NOX) activation. 
NOX is responsible for production of free radicals, 
and also it plays a role in neuronal physiology, partic-
ularly in hippocampal electrophysiology [43,83]. Data 
show a significant direct linear relationship between 
NOX activity, cognitive impairment and age-depend-
ed increase in Aβ1-42. This correlation suggests that 
oxidative stress caused by NOX-associated redox 
pathway may be another possible mechanism in 
which Aβ is involved in cognitive decline [10]. Oxida-
tive stress associated with membranes is a possible 
mechanism in which Aβ may cause synaptic dysfunc-
tion and disruption of cellular ion homeostasis [59]. 
Interestingly, mounting research show intraneuronal 
accumulation of Aβ as a possible mechanism of cog-
nitive dysfunction, especially in the early stages of 
the AD [34,45,87]. This accumulation is associated 
with morphological alterations of synapses [81] and 
with a decrease in synaptophysin around the affect-
ed neurons in AD patients [38]. Studies on 3xTg-AD 
mice showed a correlation between the cognitive 
and synaptic dysfunction with the accumulation of 
intraneuronal Aβ which occurred before formation 
of amyloid plaques [7,65]. Also hypercholesterolemia 
accelerates intraneuronal accumulation of Aβ oligo-
mers, resulting in synapse loss and memory impair-
ment [84]. This view of the complexity of the mech-
anisms and forms by which Aβ affects cognitive 
functions will be helpful for proper understanding of 
its possible interactions with PrPc.
Cooperation?
Tellingly, comprehensive studies have shown 
that out of 225 000 proteins screened in a cell mod-
el, only those with PrPc expression were strongly 
binding soluble Aβ42 [49]. It has been proposed that 
PrPc exhibits receptor affinity to β-sheet-rich con-
formers due to its ~95-110 region and the cluster of 
basic residues within the N-terminal 23-27 segment 
[14]. As to the protective functions of PrPc men-
tioned before, one may say that this protein will also 
protect the cell against Aβ, but a growing number 
of research comes with opposite findings and also 
with new controversies. Lauren et al. proposed that 
synthetic oligomeric forms of Aβ impair LTP through 
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their interactions with PrPc [49], but other studies 
did not confirm this result [1,11]. However, more nov-
el findings showed that antibodies against 94-104 
domain of PrPc blocked inhibition of LTP caused by 
soluble extracts of AD brain [2,29]. Also hippocam-
pal slices lacking PrPc were resistant to LTP inhibi-
tion by Aβ. Similar relationships can be observed 
in studies on Aβ-dependent neurotoxicity. Prnp 0/0 
mice are more resistant to neurotoxic effects of Aβ 
oligomers [44] and accordingly, over-expression of 
PrPc in neuronal cell lines increases vulnerability to 
such effects. It has been also shown that deletion of 
PrPc expression in APPswe/PSen1ΔE9 rescues 5-HT 
axonal degeneration, loss of synaptic markers and 
early death, and interestingly, Tg mice containing Aβ 
plaques, but lacking PrPc show no spatial learning 
and memory impairments [33]. APP/PS1 Tg mice, 
treated for 2 weeks with intraperitoneal injections 
of 6D11 anti-PrP antibodies, recovered in cognitive 
learning tasks behaving the same as wild-type mice 
[16]. Surprisingly, mentioned studies revealed not 
only that PrPc is not neuroprotective against Aβ, 
but even it may be necessary for its neurotoxicity 
and its impact on cognitive functions. Nevertheless, 
some authors have reached opposite conclusions. 
Rial et al. showed that Tg-20 mice characterized 
by a five-fold increase in PrPc expression was resis-
tant to a single intracerebroventricular injection of 
400 pmols/mouse of aggregated Aβ1-40, revealing 
no impairments of memory and spatial learning in 
comparison to the wild type and PrPc knockout mice. 
This resistance was accompanied with a decrease in 
activated caspase-3 protein and Bax/Bcl-2 ratio and 
reduced hippocampal cell damage [73]. Calella et al. 
[11] showed that the PrPc level had no effect on LTP 
impairment in APP/PS1 mice, and those results were 
also confirmed by Kessels et al.’s studies [41]. Also 
participation of PrPc in mediation of Ab neurotox-
icity had been challenged by results of studies on 
isolated hippocampal cells from Prnp 0/0 and Prnp 
+/+ mice. Authors concluded that PrPc in specific 
conditions may exert a relevant role in neurotoxicity 
because of sequestration of Aβ oligomers rather than 
a functional activity associated to the protein (for 
review [28]). A more recent study shed a light on the 
interactions of these proteins adding some import-
ant premise to proper understanding of the con-
troversies and the confounding results mentioned 
above. Larson et al. revealed that AD brain-purified 
Aβ dimers are specifically binding PrPc. This complex 
triggers Src Tyrosine Kinase Fyn, which activates the 
kinase and leads towards abnormal phosphorylation 
of Fyn and tau. This reaction occurs in neuronal den-
dritic spines and leads to aberrant tau missorting 
and hyperphosphorylation. Authors also revealed 
that dosage of Prnp regulates these changes. This 
comprehensive study made ex vivo, in situ, and in 
vitro indicates that this PrPc-mediated process may 
play an important role in late stages of AD, when Aβ 
dimers reach their highest level [47].
Proper understanding of this finding is facilitat-
ed by Chen et al.’s study on human neuroblastoma 
cells. They found that over-expression of PrPc down-
regulates tau protein transcription level through Fyn, 
Fyn kinase and MEK pathway. β-amyloid oligomers 
reverse this pathway by binding to PrPc, probably 
by inducing its surface retention that interferes 
with caveolae-mediated PrPc endocytosis and Fyn 
activation. Phosphorylated Fyn level increased in 
a dose-dependent manner 2 hours after Aβ oligomer 
treatment and interestingly it became decreased 
1 day after this treatment. Surprisingly, the murine 
PrPc M128V, which correspond with the high AD risk 
polymorphic human PrPc M129V [74] allele was able 
to bind Aβ oligomers, but it was unable to reverse 
the tau reduction [13]. This may be another expla-
nation why this polymorphism was associated with 
lower IQ and white matter reduction in the study 
mentioned earlier in this article.
The above authors (see ref. [13, 47], and also 
Lar son and Lesne [48]) suggest that confounding 
results about PrPc-mediated impairments, as those 
described previously, may be attributed only to a sub-
set of Aβ oligomers that are mediated through PrPc. 
For example, no dependence in LTP impairments in 
studies of Calella et al. [11] may be a result of low 
levels of Aβ dimers in young aged Tg-mice. A pro-
tective effect of PrPc over-expression against intra-
cerebroventricular injection of Aβ may be a result of 
a low concentration of its assemblies. It has been 
proven that picomolar concentrations of the Aβ did 
not trigger Fyn activation [47]. In our opinion, if PrPc 
downregulates tau protein, and Aβ binds to PrPc, 
reverting this process, it is quite possible that effects 
of Aβ will vary due to Aβ and PrPc ratio. Notewor-
thy, PrPc is not only connected in aetiology of AD by 
its direct interactions with Aβ, but also due to its 
negative modulation of BACE1 activity. PrPc declines 
with age, and is decreased in sporadic AD, but there 
are no alterations in familial AD cases. In sporadic 
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AD, the PrPc level is inversely correlated with BACE1 
activity, Aβ load, soluble Aβ, and insoluble Aβ. It is 
also inversely correlated with the stage of disease, 
as indicated by Braak tangle stages, distinguished 
according to the distribution of the tau pathology, 
especially the neurofibrillary tangles. Authors of this 
study point out that a decreased level of PrPc results 
in a decreased zinc uptake within the synapses. Such 
condition results in an elevated synaptic zinc level, 
which favours binding Aβ oligomers to the NMDA 
receptors, and mediates the excitotoxicity [86]. In 
our opinion, it is more probable that an inverse cor-
relation with Braak stage assessed tauopathy was 
caused by the elevation of Aβ and PrPc ratio, and 
its direct impact on tau expression. A biophysical 
examination of recombinant PrP revealed that this 
protein represents a unique intrinsic feature to form 
multiple non-native isoforms rich in β-sheets, which 
may result in a large spectrum of PrPc in vivo. It has 
been proved that in uninfected human brains PrP is 
presented also in the form of oligomers, and even 
large aggregates, called insoluble PrPc (iPrPc) which 
stand for ~5-25% of total PrP. It is proposed that if 
soluble PrPc can bind to soluble Aβ42, also iPrP
c will 
bind insoluble Aβ, modulating its deposition [91]. It 
is therefore consistent with Takahashi et al.’s find-
ings [82] (confirming the prior report of Ferrer et 
al. [27]) indicating that PrPc is present in amyloid 
deposits. Many other related issues remain seeming-
ly untouched. For example, amyloid Aβ deposits are 
formed within vessels and amyloid angiopathy is not 
only limited to arteries, but also affects veins [60]. 
It is interesting whether there is also an interaction 
between Aβ and PrPc in this compartment of brain 
tissue. To summarize, a growing number of research 
indicate new possible functions of PrPc in the field 
of cognition, both in its physiological and patho-
physiological aspects. Considering new data, we are 
compelled to stronger appreciate the role of soluble 
forms of Aβ in the pathomechanism of AD, which 
possibly even prevails over its insoluble deposits. 
This may be regarded as a “paradigm shift” in an 
understanding of cognitive decline in AD. Despite 
the remaining controversies, recent findings prompt 
us to consider that roads of PrPc and Aβ meet at 
the point of tauopathy and moreover, formation of 
PrPc-Aβ complexes may result in the consumption 
of PrPc, what modulates Aβ neurotoxicity, possibly 
depriving nervous tissue of the neuroprotective 
function of PrPc.
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